Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors

Company Founded by MPM Capital, with Financing Co-Led by MPM Capital, EcoR1 Capital and Vida Ventures Proprietary Technology Platform Harnesses the Power of Alpha Particles to Target Solid Tumors Company Led by Industry Veteran Matthew Roden, PhD, Pr... Biopharmaceuticals, Oncology, Venture Capital, Personnel Aktis Oncology, radiopharmaceuticals, alpha radiotherapy, radiotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news